IAM Patent 1000 identifies Simon as a “recommended individual” for his expertise in Biotechnology. Simon is reported to have “the ear of venture capitalists” and is “an influential figure in many of Europe’s IP organisations”. Legal 500 describes him as an “excellent lawyer”.
Simon has over 30 years’ experience of patent work, including drafting and filing patent applications throughout the world – in particular, before the European Patent Office (EPO). He handles prosecution, as well as opposition and appeal work, primarily in the life sciences.
His technical work covers vaccines, pharmaceuticals, fermentation technology, pharmaceutical and nutritional uses of polyunsaturated fatty acids, astaxanthin and Vitamin B12 and greentech (eco-friendly algae plant technology). He also handles cases on gene therapy, personalised nutrition, biofuels, liposome technology, cancer biomarkers, micro-arrays, stem cells, in vitro fertilisation and CRISPR technology.
Simon’s clients range from US multinational companies to small UK academic organisations and small and medium-sized enterprises (SMEs). He has been involved in oppositions and appeals concerning human pheromones, Hoffman-La Roche’s polymerised chain reaction patents, ultrasound contrast agents, medical devices (for measuring glucose levels), nutritional uses of arachidonic acid (ARA), vaccines and anti-prolactin agents.
Simon was involved in the seminal EPO Board of Appeal Decision T820/92 concerning contraceptive methods involving the administration of luteinising hormone-releasing hormone to women. He also acted as an expert witness and gave evidence to the English High Court in the HGS v Eli Lilly litigation, which led to the first ever Supreme Court decision on a patent matter (concerning industrial applicability).
Simon is a member of the governing Councils for both professional institutes, the Chartered Institute of Patent Agents (CIPA) and the Institute of Representatives before the EPO (epi). He currently chairs the CIPA Life Sciences Committee, which organises an annual biotech conference in the UK late November. Mr Wright is also the Secretary of the epi Biotech Committee. This gives him a valuable insight into future legislative and practice changes, in particular before the EPO, and the opportunity to influence future legislation.
Simon joined J A Kemp in 1994, after working in private practice elsewhere since 1986, and became a partner in 1999.
University of Bristol, Honours Degree in Chemistry (Specialist options in Biochemistry)
European Patent Attorney; UK Chartered Patent Attorney
Fellow of the Chartered Institute of Patent Attorneys (CIPA); Member of the Institute of Professional Representatives before the European Patent Office (EPI); Chairman of the CIPA Life Sciences Committee; Secretary of the EPI Biotechnological Inventions Committee; Member of the CIPA Governing Council and Patents Committee; UK Member of EPI Governing Council, By Laws and EP Patent (Pharma) Committees